Valuation: PROT DIAG

Market Cap 217M 22.88M 19.79M 18.48M 16.95M 31.88M 2.18B 32.39M 85.1M 1.09B 85.91M 84.03M 3.61B P/E 2024
-2.94x
P/E 2025 -4.28x
Enterprise Value 176M 18.59M 16.08M 15.02M 13.78M 25.91M 1.77B 26.32M 69.16M 887M 69.82M 68.29M 2.93B EV / Sales 2024
2.16x
EV / Sales 2025 4.15x
Free-Float
12.26%
Yield 2024 *
-
Yield 2025 -
1 day+2.86%
1 week+0.56%
Current month+0.56%
1 month+36.99%
3 months+24.48%
6 months-3.85%
Current year+0.56%
1 week 17.48
Extreme 17.48
18.2
1 month 12.98
Extreme 12.98
18.68
Current year 12.46
Extreme 12.46
21
1 year 12.46
Extreme 12.46
25.3
3 years 11.7
Extreme 11.7
110
5 years 11.7
Extreme 11.7
180
10 years 11.7
Extreme 11.7
806
Manager TitleAgeSince
Chief Executive Officer 62 01/07/2020
Director of Finance/CFO 68 -
Chief Tech/Sci/R&D Officer 57 -
Director TitleAgeSince
Director/Board Member 70 01/01/2020
Director/Board Member 62 -
Director/Board Member 52 01/10/2023
Change 5-day change 1-year change 3-year change Capi.($)
+2.86%+0.56%-27.13%-86.26% 22.88M
+1.18%+6.51%+28.29%-32.97% 16.86B
+4.02%-1.28%-6.98%+108.76% 1.75B
+2.21%+2.13%-29.08%+29.83% 1.01B
-24.72%-26.74%-48.62%-85.07% 842M
+2.52%+3.63%-36.96%-49.42% 679M
+3.27%+0.84%-48.14%-50.23% 548M
+1.31%+10.90%+30.91%-44.35% 523M
+4.95%+10.97%-44.20%-43.92% 417M
+3.11%+3.53%-7.97%-23.99% 384M
Average +0.07%+3.06%-18.99%-27.76% 2.3B
Weighted average by Cap. +0.69%+5.00%+14.63%-22.61%

Financials

2024 2025
Net sales 36.33M 3.83M 3.32M 3.1M 2.84M 5.34M 365M 5.43M 14.26M 183M 14.39M 14.08M 604M 42.2M 4.45M 3.85M 3.6M 3.3M 6.21M 424M 6.3M 16.56M 212M 16.72M 16.35M 702M
Net income -26.94M -2.84M -2.46M -2.3M -2.11M -3.96M -271M -4.02M -10.57M -136M -10.67M -10.44M -448M -49.71M -5.24M -4.54M -4.24M -3.89M -7.31M -499M -7.43M -19.51M -250M -19.7M -19.26M -827M
Net Debt -15.73M -1.66M -1.44M -1.34M -1.23M -2.31M -158M -2.35M -6.18M -79.19M -6.23M -6.1M -262M -40.61M -4.28M -3.71M -3.46M -3.17M -5.97M -408M -6.07M -15.94M -204M -16.09M -15.74M -676M
Logo PROT DIAG
Prolight Diagnostics AB (publ) is a Sweden-based medical technology company. Together with Technology Partners, the Company develops patient-close test systems based on patented technology, for use in so-called Point of Care Testing (POCT). POCT tests are performed outside the traditional hospital laboratory, small mobile instruments enable testing near the patient and provide quick test answers. The Company focuses on the heart marker troponin.
Employees
22
Date Price Change Volume
07/08/26 SEK 18.00 +2.86% 16,081
06/08/26 SEK 17.50 -3.85% 3,746
05/08/26 SEK 18.20 +4.12% 9,799
04/08/26 SEK 17.48 -2.89% 3,640
03/08/26 SEK 18.00 +0.56% 12,058
  1. Stock Market
  2. Stocks
  3. PRLD Stock